Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • ABBV-022
    • Onco IX
    • OncoFAP
    • FAP-IL12
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dekavil
    • Dodekin
    • Onco IX
    • OncoFAP
    • FAP-IL12
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)

Philogen announces enrolment of 214 patients in the Nidlegy™ Phase III European clinical trial for the treatment of locally advanced melanoma

Jul 25, 2022 | 2022, Press Releases, Scientific

More details

Deposito del Verbale dell’Assemblea degli Azionisti (Price sensitive)

Jun 29, 2021 | Investors, Press Releases

Philogen S.p.A. rende noto che il verbale dell’Assemblea degli Azionisti tenutasi il giorno 31 maggio 2021, in sede ordinaria e straordinaria, è a disposizione del pubblico presso la sede legale della Società a Siena, Piazza La Lizza, 7, sul sito internet della...

Comunicato Deliberazioni Assemblea / Press release Shareholders’ meeting decisions (Price sensitive)

May 31, 2021 | Investors, Press Releases

L’Assemblea degli Azionisti di Philogen S.p.A. si è riunita in data 31/05/2021, in sede ordinaria e straordinaria. Download PDF document

Recent Posts

  • Philogen to attend the European Bispecific and Multispecific Antibody congress in Amsterdam on the 22nd and 23rd of February, 2023
  • Philogen to attend the 7th Annual Next-Gen Immuno-Oncology Conference congress in London on the 9th and 10th of March, 2023
  • 23 gennaio 2023 – Aggiornamento sul programma di acquisto di azioni proprie
  • 16 gennaio 2023 – Aggiornamento sul programma di acquisto di azioni proprie
  • 09 gennaio 2023 – Aggiornamento sul programma di acquisto di azioni proprie

Recent Comments

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it